Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06638671 · ClinicalTrials.gov registry record · Phase 4
Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity
A Phase 4 study of Exercise Capacity and Metformin, sponsored by University of Virginia.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06638671 is a Phase 4 study of Exercise Capacity and Metformin that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06638671, a Phase 4 study of Exercise Capacity and Metformin, is actively recruiting participants, sponsored by University of Virginia.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Metformin is the most prescribed blood sugar (glucose)-lowering medication for patients diagnosed with type 2 diabetes mellitus (T2DM). Metformin stimulates glucose uptake in skeletal muscle similar to the effects of exercise, though, some studies report that metformin may decrease exercise capacity. The main question this study looks to answer is: • Does metformin alter exercise capacity? Participants will: * Complete 5 exercise tests on a stationary bike. * Undergo a body composition test. * Take metformin and placebo. * Complete food and symptom logs. The researchers hypothesize that: • Metformin will reduce aerobic capacity.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Metformin Hydrochloride
Study Locations (1)
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-01-31 |
| Est. Completion | 2026-04-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06638671
The ClinicalTrials.gov registry entry for NCT06638671 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Exercise Capacity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06638671 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT06638671 about?
NCT06638671 is a clinical study titled "Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity". Metformin is the most prescribed blood sugar (glucose)-lowering medication for patients diagnosed with type 2 diabetes mellitus (T2DM). Metformin stimulates glucose uptake in skeletal muscle similar to the effects of exercise, though, some studies report that metformin may decrease exercise capacity...
What is the current status of trial NCT06638671?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2025-01-31. Estimated completion is 2026-04-01.
What conditions does trial NCT06638671 study?
This clinical trial studies the following conditions: Exercise Capacity, Metformin.
What interventions are being tested in trial NCT06638671?
The interventions under investigation include: Placebo (DRUG), Metformin Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT06638671?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06638671 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Exercise Capacity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.